Arnold Cinman, MD
Urology · Los Angeles, CANPI 1801867163
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Avyxa Pharma, LLC at 35.4% of the total. 2025 is the largest year on record at $4,691, 4.6 times the $1,012 reported in 2019.
Across 171 payments — averaging $65.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avyxa Pharma, LLC$4K
- Ferring Pharmaceuticals Inc.$3K
- Johnson & Johnson$1K
- Pfizer$590
- Astellas Pharma US Inc$525
- Dendreon Pharmaceuticals LLC$406
- plus $2K from 22 others
Across 75 payments — averaging $1283.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$96K
- Astellas Pharma Global Development$331
What the payments were for
- Consulting fees$2,80025%
- Speaking & faculty fees$2,00018%
- Travel & lodging$1,66115%
- Food & beverage$4,56841%
- Education$891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avyxa Pharma, LLC | 7 | $3,937 |
| Ferring Pharmaceuticals Inc. | 5 | $2,774 |
| Johnson & Johnson(2 entities) | 31 | $1,028 |
| Pfizer | 27 | $590 |
| Astellas Pharma US Inc | 25 | $525 |
| Dendreon Pharmaceuticals LLC | 10 | $406 |
| AbbVie | 10 | $243 |
| Teleflex LLC | 3 | $217 |
| Myriad Genetic Laboratories, Inc. | 10 | $159 |
| Blue Earth Diagnostics | 5 | $146 |
| Coloplast | 7 | $136 |
| Telix Pharmaceuticals | 4 | $118 |
| Dornier Medtech America, Inc | 1 | $102 |
| Comsort, Inc | 1 | $100 |
| Merck | 3 | $89 |
| Profound Medical Corp. | 1 | $88 |
| Sumitomo Pharma America, Inc. | 3 | $79 |
| AstraZeneca | 4 | $73 |
| Myovant Sciences Inc. | 3 | $71 |
| Immunitybio, Inc. | 2 | $45 |
| Boston Scientific | 2 | $32 |
| Amgen | 1 | $29 |
| Bayer | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $25 |
| ABC Home Medical Supply, Inc. | 1 | $24 |
| Axonics, Inc. | 1 | $22 |
| KARL Storz Endoscopy-america | 1 | $22 |
| Hollister Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADSTILADRIN$2,700
- Erleada$420
- AKEEGA$137
- UroLift System$109
- Dornier MedTech$102
- KEYTRUDA$100
How this compares
$11,118 in reported general payments places this provider in the 80th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 19 | $289,338 |
| GemtesaVibegron | 80 | $54,688 |
| MyrbetriqMirabegron | 20 | $20,780 |
| Tamsulosin Hcl | 483 | $7,097 |
| XyostedTestosterone Enanthate | 11 | $6,409 |
| Dutasteride | 191 | $4,964 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 35 | $4,862 |
| Finasteride | 246 | $3,937 |
| Potassium Citrate ErPotassium Citrate | 28 | $2,672 |
| Tadalafil | 30 | $2,412 |
| Estradiol | 14 | $1,092 |
| Oxybutynin Chloride ErOxybutynin Chloride | 18 | $1,091 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 46 | $572 |
| Testosterone | 13 | $503 |
| Trimethoprim | 12 | $349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $1,028 | $289,33819 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $79 | $54,68880 claims |
| Astellas Pharma US IncMyrbetriq | $525 | $20,78020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,324 urology providers in California.
Other urology in Los Angeles
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Stuart HoldenLos Angeles$1.1M
- William AronsonLos Angeles$540K
- Amir LebastchiLos Angeles$478K
- Nazy ZomorodianLos Angeles$309K
- Jeffrey Loh-DoyleLos Angeles$308K
- Siamak DaneshmandLos Angeles$306K
- Karim ChamieLos Angeles$291K
- Brian ShuchLos Angeles$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.